24 Apr

Why high-tech patent expertise will be increasingly valued by life sciences companies

Following a recent interview with NantWorks’ IP chief Mark Kokes, IAM’s Adam Houldsworth argues that leading high-tech patent strategists are likely to enjoy more opportunities in the pharma and biotech sectors in years to come

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth